AI Engines For more Details: Perplexity Kagi Labs You
Stress Response: Catecholamines are released by the adrenal glands in response to stress, activating the body's "fight or flight" response. They increase heart rate, blood pressure, and blood flow to muscles, preparing the body to respond to a perceived threat or danger. Chronic activation of the stress response and prolonged elevation of catecholamine levels may contribute to the development of stress-related disorders such as anxiety, depression, and cardiovascular disease.
Neurotransmission: In the brain, catecholamines act as neurotransmitters, transmitting signals between nerve cells and regulating mood, attention, motivation, and other cognitive functions. Dopamine, in particular, is involved in the brain's reward system and plays a key role in motivation, pleasure, and reinforcement learning. Dysregulation of dopamine signaling has been implicated in various psychiatric disorders, including schizophrenia, bipolar disorder, and addiction.
Cardiovascular Function: Norepinephrine and epinephrine are important regulators of cardiovascular function. They increase heart rate, contractility, and cardiac output, leading to increased blood flow to the muscles and vital organs during times of stress or physical exertion. However, excessive catecholamine release can lead to hypertension, arrhythmias, and other cardiovascular complications.
Metabolism: Catecholamines influence metabolism by stimulating the breakdown of glycogen into glucose in the liver and promoting lipolysis (breakdown of fats) in adipose tissue. This provides the body with a quick source of energy during times of stress or physical activity. Dysregulation of catecholamine signaling can contribute to metabolic disorders such as obesity, insulin resistance, and diabetes.
Respiratory Function: Catecholamines play a role in regulating respiratory function by increasing the rate and depth of breathing during periods of increased oxygen demand, such as exercise or stress. Epinephrine, in particular, can dilate the airways and improve airflow to the lungs, making it a key component of emergency treatment for severe asthma attacks and anaphylaxis.
Rank | Probiotic | Impact |
---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.6 | -0.6 | |
ADHD | 0.6 | -0.6 | |
Allergic Rhinitis (Hay Fever) | 0.6 | 0.8 | -0.33 |
Allergies | 0.6 | 0.6 | 0 |
Allergy to milk products | 2 | 1.2 | 0.67 |
Alopecia (Hair Loss) | 0.6 | -0.6 | |
Alzheimer's disease | 0.6 | 2.2 | -2.67 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.6 | 1.2 | -1 |
Ankylosing spondylitis | 1.4 | 2.6 | -0.86 |
Anorexia Nervosa | 0.6 | -0.6 | |
Antiphospholipid syndrome (APS) | 0.8 | -0.8 | |
Asthma | 0.8 | 1.2 | -0.5 |
Atrial fibrillation | 1.2 | 1.4 | -0.17 |
Autism | 3.8 | 2.8 | 0.36 |
Barrett esophagus cancer | 0.6 | -0.6 | |
benign prostatic hyperplasia | 0.4 | -0.4 | |
Bipolar Disorder | 1 | -1 | |
Brain Trauma | 1.2 | -1.2 | |
Carcinoma | 0.8 | -0.8 | |
Celiac Disease | 0.6 | 1.2 | -1 |
Chronic Fatigue Syndrome | 1.2 | -1.2 | |
Chronic Kidney Disease | 1 | -1 | |
Chronic Lyme | 0.6 | -0.6 | |
Chronic Urticaria (Hives) | 0.8 | -0.8 | |
Coagulation / Micro clot triggering bacteria | 1.4 | -1.4 | |
Colorectal Cancer | 2.2 | -2.2 | |
Constipation | 2 | -2 | |
COVID-19 | 1.8 | 2.2 | -0.22 |
Crohn's Disease | 0.8 | 3 | -2.75 |
cystic fibrosis | 0.8 | -0.8 | |
deep vein thrombosis | 1.4 | -1.4 | |
Depression | 1.6 | 3.2 | -1 |
Dermatomyositis | 0.6 | -0.6 | |
Eczema | 1 | -1 | |
Endometriosis | 2.2 | -2.2 | |
Eosinophilic Esophagitis | 0.6 | -0.6 | |
Epilepsy | 1.8 | -1.8 | |
Functional constipation / chronic idiopathic constipation | 0.6 | 2.4 | -3 |
gallstone disease (gsd) | 1 | -1 | |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | -0.6 | |
Generalized anxiety disorder | 1.2 | -1.2 | |
Graves' disease | 0.6 | 0.6 | |
Hashimoto's thyroiditis | 0.6 | 0.2 | 2 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2.2 | -2.2 | |
hyperglycemia | 0.4 | -0.4 | |
Hyperlipidemia (High Blood Fats) | 0.2 | 1.6 | -7 |
hypersomnia | 0.6 | -0.6 | |
hypertension (High Blood Pressure | 0.6 | 1 | -0.67 |
Hypothyroidism | 0.6 | 0.6 | |
IgA nephropathy (IgAN) | 0.6 | -0.6 | |
Inflammatory Bowel Disease | 1.2 | 2.6 | -1.17 |
Insomnia | 0.6 | 0.6 | |
Irritable Bowel Syndrome | 1.8 | 3.4 | -0.89 |
Liver Cirrhosis | 2.2 | -2.2 | |
Long COVID | 1 | 3.2 | -2.2 |
Lung Cancer | 0.4 | -0.4 | |
Metabolic Syndrome | 3.2 | -3.2 | |
Mood Disorders | 2.2 | 3.2 | -0.45 |
Multiple Sclerosis | 1.2 | -1.2 | |
myasthenia gravis | 0.6 | 0.6 | |
Neuropathy (all types) | 0.8 | 0.6 | 0.33 |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2 | -2 | |
Obesity | 0.8 | 3 | -2.75 |
obsessive-compulsive disorder | 2.8 | -2.8 | |
Osteoarthritis | 0.2 | -0.2 | |
Osteoporosis | 0.4 | -0.4 | |
Parkinson's Disease | 1 | 2.2 | -1.2 |
Polycystic ovary syndrome | 1.8 | -1.8 | |
Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
Psoriasis | 0.8 | 0.8 | |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.2 | 3.2 | -1.67 |
Rosacea | 0.8 | 0.8 | |
Schizophrenia | 1.2 | 1.2 | 0 |
Sjögren syndrome | 0.6 | 0.4 | 0.5 |
Sleep Apnea | 1 | -1 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.6 | -1.6 | |
Stress / posttraumatic stress disorder | 0.6 | 1 | -0.67 |
Systemic Lupus Erythematosus | 1.2 | 2.4 | -1 |
Type 1 Diabetes | 0.6 | 1.4 | -1.33 |
Type 2 Diabetes | 0.6 | 3.2 | -4.33 |
Ulcerative colitis | 1.4 | 2.6 | -0.86 |
Unhealthy Ageing | 0.6 | -0.6 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.